DOCSLIB.ORG

Do Alpha Blockers Cause Heart Failure and Stroke? Observations from ALLHAT

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Do Alpha Blockers Cause Heart Failure and Stroke? Observations from ALLHAT Journal of Human Hypertension (2000) 14, 287–289 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh COMMENTARY Do alpha blockers cause heart failure and stroke? Observations from ALLHAT DG Beevers and GYH Lip University Department of Medicine, City Hospital, Birmingham, UK Keywords: alpha blockers; heart failure; strokes The Antihypertensive and Lipid Lowering treatment of 2.04 (95% CI 1.79–2.32), which was seen across to prevent Heart Attack Trial (ALLHAT) is one of gender, age, and ethnic subgroups. The relative risk two current mega-trials (the other being the Anglo- for stroke was also increased in the doxazosin group Scandinavian Cardiac Outcomes Study, ASCOT), (RR 1.19 (95% CI 1.01–1.14; P = 0.04)). Chlorthali- with over 42 000 ‘high-risk’ antihypertensive done, which is a much cheaper drug, therefore patients with two objectives: firstly, to assess appeared superior to doxazosin for hypertension whether the newer antihypertensive agents control, drug compliance, and reduction of cardio- (amlodipine, lisinopril, and doxazosin) reduce the vascular complications. incidence of coronary artery disease (CAD) when Whilst the alpha blockers have been available for compared with a diuretic (chlorthalidone); and sec- a great many years they have never been subjected ondly, whether statin therapy in hypertensive to a long-term outcome trial in hypertension. In the patients with moderate hypercholesterolaemia will short-term they seem attractive because not only do reduce cardiac events compared with placebo. they lower blood pressure but they also have mildly Patients were randomised to one of the above four beneficial effects on plasma lipid levels and also antihypertensive agents, with a planned follow-up appear to improve insulin sensitivity.3 The early of 4–8 years.1 alpha blocker, prazocin, was not popular because of On 24 January, 2000, the independent review a rapid first dose effect sometimes causing postural committee recommended termination of the doxazo- hypotension. Furthermore, it had to be given three sin arm on account of a 25% higher rate of the com- times per day.4 The arrival of doxazosin and its com- bined cardiovascular disease (CVD), a major second- petitor terazosin seemed to be a major break- ary end-point, when compared to the patients through.5 Because of the lack of long-term outcome taking chlorthalidone.2 data of the use of doxazosin at first-line therapy, it The interim results were presented in March 2000 is always tended to be a drug used in reserve for at the American College of Cardiology meeting in patients whose blood pressures are resistant to other Anaheim, California, by Dr Barry Davis. The therapies. For example in the ASCOT trial doxazo- patients in both the doxazosin arm (n = 9067) and sin is the third-line drug to add-in to either atenolol the chlorthalidone group (n = 15268) were very simi- with bendrofluazide or perindopril with amlodip- lar for baseline characteristics, and at 4 years, 86% ine.6 There are also favourable reports of the use of of patients randomised to chlorthalidone were still doxazosin together with the angiotensin-converting taking the drug (vs 75% in the doxazosin arm). At enzyme (ACE) inhibitors.7 4 years, the mean systolic blood pressure was 135 The adverse effects of doxazosin appear until now mm Hg in the chlorthalidone group and 137 mm Hg to be related to symptomatic side-effects. The pres- in the doxazosin arm, with similar mean diastolic ence of alpha receptors at the bladder neck leads to blood pressures. There was no difference in the rela- relaxation of the urethra. This is a beneficial effect in tive risk (RR) of CAD between patients receiving men as it relieves the symptoms of benign prostatic doxazosin and those receiving chlorthalidone (RR hypertrophy.8 Alpha blockers have already been 1.03; 95% CI 0.9–1.17), but the relative risk of com- used for this condition even in people who do not bined CVD in the doxazosin arm compared with the have high blood pressure. The effect however on the Ͻ chlorthalidone arm was 1.25 (95% CI 1.17–1.33; P alpha-receptors in the bladder neck is disadvan- 0.0001), with the event curves diverging early. This tageous in women and may lead to stress or urge effect was mainly related to an increased relative incontinence.9 Very occasionally patients do com- risk of heart failure in the patients taking doxazosin, plain of what sounds like first dose hypotension and for that reason doxazosin is still often started with Correspondence: Prof DG Beevers the first few doses to be taken at night. This pre- Received and accepted 24 March 2000 caution was absolutely necessary for patients receiv- Do alpha blockers cause heart failure and stroke? DG Beevers and GYH Lip 288 ing prazosin but was hoped it would be less neces- ember 1999.17 It will be interesting to see whether sary for patients on doxazosin. The arrival of a the guidelines committees of the various National longer acting gastrointestinal transfer system (GITS) and International Hypertension Societies will mod- formulation of doxazosin 8 mg was awaited with ify their recommendations that alpha blockers can interest. be used for first-line therapy.18 It is certainly doubt- The adverse findings in the ALLHAT study must ful whether the alpha blockers should cease to be be looked at with caution at this stage. Clearly more used as ‘add-in’ drugs where the first-line therapies information will become available. Indeed, the anti- have failed, because the hazards of uncontrolled hypertensive effect of doxazosin appears to be as hypertension may well override the possible hazard good as that with the comparator drugs. In the Treat- of alpha-blocking drugs. ment of Mild Hypertension Study (TOMHS) doxazo- sin was equally effective as chlorthalidone, and had similar effects on echocardiographic left ventricular References size.10 In time we will perhaps learn whether the 1 Davis BR et al. Rationale and design for the Antihyper- patients who were randomised to receive doxazosin tensive and Lipid Lowering Treatment to Prevent in ALLHAT differed in any way from those random- Heart Attack Trial (ALLHAT). ALLHAT Research ised to the other drugs in respect of important Group. Am J Hypertens 1996; 9: 342–360. baseline parameters such as left ventricular size or 2 Messerli FH. Implications of discontinuation of dox- function. azosin arm of ALLHAT. Lancet 2000; 355: 863–864. Assuming that the adverse effects of doxazosin in 3 Nash DT. Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipopro- ALLHAT are not due to confounding variables or tein metabolism. Clin Cardiol 1990; 13: 764–772. systematic sources of bias, the next question is 4 Bendall MJ, Balock KH, Wilson PR. Side effects due to whether this adverse effect sounds plausible. What the treatment of hypertension with prazosin. BMJ might the mechanisms be? In the past alpha blockers 1975; 2: 727–728. were considered as possible drugs for the treatment 5 Kaplan NM. Alpha blockers. In: Messerli FH (ed). The of heart failure and were not thought to be likely to ABCs of Antihypertensive Therapy. 2nd edn. Authors’ cause it or to make it worse.11 Whilst the difference Publishing House: New York, 2000, pp 99–110. between prazosin and placebo was not statistically 6 Oparil S. Long term morbidity and mortality trials significant, close examination of data on 642 men with amlodipine. J Cardiovasc Pharmacol 1999; 33 from the Vasodilator-Heart Failure Trial-1 (VeHFT- (Suppl 2): S1–S6. 7 Brown MJ, Dickerson SEC. Synergism between alpha1- I) revealed 91 deaths (49.7%) in the prazosin group, blockade and angiotensin concerting enzyme inhi- compared to 120 deaths (44.0%) in those on placebo bition in essential hypertension. J Hypertens 1991; 9 and 72 deaths (38.7%) in the hydralazine-nitrate (Suppl 6): S362–S363. group.11 By reducing peripheral vascular resistance, 8 Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An the alpha-receptor blockers should reduce left ven- update of its clinical pharmacology and therapeutic tricular after-load and therefore have effects which applications in hypertension and benign prostatic are beneficial and somewhat similar to those seen hyperplasia. Drugs 1995; 49: 295–320. with ACE inhibitors or hydralazine with nitrates.12 9 Marshall HJ, Beevers DG. Alpha-adrenoceptor blocking Short-term studies suggested that alpha blockers drugs and female urinary incontinence: prevalence might have beneficial haemodynamic effects in and reversibility. Br J Clin Pharmacol 1996; 42: 507– 13–15 509. patients with heart failure. These findings how- 10 Neaton JD et al. Treatment of mild hypertension study. ever were mainly confined to patients receiving pra- Final results. JAMA 1993; 270: 713–724. zosin and not doxazosin. 11 Cohn JN et al. Effect of vasodilator therapy on mor- It is generally considered that doxazosin has neu- tality in chronic congestive heart failure. Results of a tral effects on the renin-angiotensin system and does Veterans Administration Cooperative Study. N Engl J not cause any activation or suppression.16 In that Med 1986; 314: 1547–1552. respect alpha blockers might seem more rather than 12 Toth K et al. Hemorheological and hemodynamic para- less attractive than chlorthalidone which can cause meters in patients with essential hypertension and a small shrinkage in plasma volume associated with their modification by alpha-1 inhibitor drug treatment. a rise in plasma renin levels. Clin Hemorheol Microcirc 1999; 2: 209–216. 13 Horowitz JD et al. Haemodynamic effects of a single Clearly the doxazosin ‘crisis’ will be a source of low dose of prazosin in patients with chronic conges- much discussion in the coming months. We must tive cardiac failure correlations with pharmacokinet- be careful not to overreact.
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Pharmacology in MS Advanced Practice Management
    Pharmacology in MS Advanced Practice Management Heidi Maloni APRN, BC [email protected] Objectives • Discuss basic principles of pharmacology, pharmacokinetics and pharmacodynamics. • Describe the pharmacotherapeutics of drugs used in MS • Identify the role of advanced practice nurse in MS pharmacological management. Advanced Practice Pharmacology Background • Pharmacology: study of a drug’s effects within a living system • Each drug is identified by 3 names: chemical, generic, trade or marketing name N-4-(hydroxyphenyl) acetamide; acetaminophen; Tylenol sodium hypochlorite; bleach; Clorox 4-(diethylamino)-2-butynl ester hydrochloride; oxybutynin chloride; Ditropan • Drugs are derived from: plants, humans, animals, minerals, and chemical substances • Drugs are classified by clinical indication or body system APN Role Safe drug administration Nurses are professionally, legally, morally, and personally responsible for every dose of medication they prescribe or administer Know the usual dose Know usual route of administration Know significant side effects Know major drug interactions Know major contraindication Use the nursing process Pregnancy Safety • Teratogenicity: ability to produce an abnormality in the fetus (thalidomide) • Mutogenicity: ability to produce a genetic mutation (diethylstilbestrol, methotrexate) Pregnancy Safety Categories • A: studies indicate no risk to the fetus (levothyroxan; low dose vitamins, insulin) • B: studies indicate no risk to animal fetus; information in humans is not available (naproxen;acetaminophen; glatiramer
    [Show full text]
  • ALLHAT Protocol, Can Enter the Trial at the Discretion of the Principal Investigator Or His/Her Designee
    Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Protocol Revised: March 1995 May 1995 April 1998 April 2000 April 2000 Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Protocol Table of Contents Page I. Overview............................................................................................................................ 2 II. Background........................................................................................................................ 4 III. Hypotheses and Study Power ........................................................................................... 10 IV. Eligibility and Exclusions................................................................................................. 13 V. Recruitment....................................................................................................................... 17 VI. Antihypertensive Intervention .......................................................................................... 22 VII. Cholesterol-Lowering Intervention................................................................................... 26 VIII. Laboratory Measurements ................................................................................................ 28 IX. Outcome Measurements.................................................................................................... 30 X. Study Organization ..........................................................................................................
    [Show full text]
  • Benign Prostatic Hyperplasia (BPH) Treatments Review 10/05/2009
    Benign Prostatic Hyperplasia (BPH) Treatments Review 10/05/2009 Copyright © 2004 - 2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein,
    [Show full text]
  • Antiparasitic Properties of Cardiovascular Agents Against Human Intravascular Parasite Schistosoma Mansoni
    pharmaceuticals Article Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni Raquel Porto 1, Ana C. Mengarda 1, Rayssa A. Cajas 1, Maria C. Salvadori 2 , Fernanda S. Teixeira 2 , Daniel D. R. Arcanjo 3 , Abolghasem Siyadatpanah 4, Maria de Lourdes Pereira 5 , Polrat Wilairatana 6,* and Josué de Moraes 1,* 1 Research Center for Neglected Diseases, Guarulhos University, Praça Tereza Cristina 229, São Paulo 07023-070, SP, Brazil; [email protected] (R.P.); [email protected] (A.C.M.); [email protected] (R.A.C.) 2 Institute of Physics, University of São Paulo, São Paulo 05508-060, SP, Brazil; [email protected] (M.C.S.); [email protected] (F.S.T.) 3 Department of Biophysics and Physiology, Federal University of Piaui, Teresina 64049-550, PI, Brazil; [email protected] 4 Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran; [email protected] 5 CICECO-Aveiro Institute of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand * Correspondence: [email protected] (P.W.); [email protected] (J.d.M.) Citation: Porto, R.; Mengarda, A.C.; Abstract: The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, Cajas, R.A.; Salvadori, M.C.; Teixeira, a disease of great global public health significance. Praziquantel is the only drug available to F.S.; Arcanjo, D.D.R.; Siyadatpanah, treat schistosomiasis and there is an urgent demand for new anthelmintic agents.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Comparison of Different Alpha-Blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
    대한남성과학회지：제 29 권 제 3 호 2011년 12월 Korean J Androl. Vol. 29, No. 3, December 2011 http://dx.doi.org/10.5534/kja.2011.29.3.242 Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms Keon Cheol Lee1, Jong Gu Kim2, Sung Yong Cho1, Joon Sung Jeon1, In Rae Cho1 Department of Urology, 1Inje University Ilsanpaik Hospital, Goyang, 2Happy Urology Clinic, Ansan, Korea =Abstract= Purpose: We compared the efficacy and safety profiles of dose increase, traditional combination methods, and combining different alpha blockers in hypertensive males with lower urinary tract symptom (LUTS) refractory to an initial dose of 4 mg doxazosin. Materials and Methods: Between 2000 and 2005, 374 male patients with LUTS and hypertension unresponsive to 4 weeks of 4 mg doxazosin were enrolled. The subjects were randomly classified into 3 groups, 8 mg/day of doxazosin (D group), 4 mg of doxazosin plus 0.2 mg/day of tamsulosin (DT group), and 4 mg doxazosin plus 5 mg/day finasteride (DF group). Patients were evaluated based on their International Prostate Symptom Score (IPSS), quality of life (QOL), uroflowmetry and blood pressure (BP) and adverse events (AEs) at the baseline and 3 and 12 months after treatment. Results: The 269 patients (71.9%) were followed for at least 1 year (D group n=84, DT group n=115, and DF group n=70). The clinical parameters before and after initial 4 mg/day doxazosin were not different among the 3 groups. IPSS improvement after 3 months and maximal flow rate (Qmax) improvement after 3 and 12 months were significantly higher in the D and DT groups than the DF group (p＜0.05).
    [Show full text]
  • Different Effects of Propranolol, Bisoprolol, Carvedilol and Doxazosin on Heart Rate, Blood Pressure, and Plasma Concentrations of Epinephrine and Norepinephrine K
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2003; 6 (1-4), 69-72 Different Effects of Propranolol Bisoprolol, Carvedilol and Doxazosin on Heart Rate, Blood Pressure, and Plasma Concentrations of Epinephrine and Norepinephrine Stoschitzky K, Donnerer J, Klein W, Koshucharova G Kraxner W, Lercher P, Maier R, Watzinger N, Zweiker R Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL CARDIOLOGY Alpha- Versus Beta-Blockers J Clin Basic Cardiol 2003; 6: 69 Different Effects of Propranolol, Bisoprolol, Carvedilol and Doxazosin on Heart Rate, Blood Pressure, and Plasma Concentrations of Epinephrine and Norepinephrine K. Stoschitzky1, G. Koshucharova1, R. Zweiker1, P. Lercher1, R. Maier1, N. Watzinger1, W. Kraxner1, W. Klein1, J. Donnerer2 Background: Despite of its beta-blocking effects, carvedilol has been shown not to decrease resting heart rate in healthy subjects. Therefore, we compared haemodynamic effects of carvedilol (an alpha- and beta-blocker), propranolol (a non-selec- tive beta-blocker), bisoprolol (a beta1-selective beta-blocker), doxazosin (an alpha-blocker) and placebo, at rest and during exercise. In addition, we measured plasma levels of epinephrine and norepinephrine. Methods: Twelve healthy males received single oral doses of 80 mg propranolol, 5 mg bisoprolol, 50 mg carvedilol, 4 mg doxazosin and placebo according to a randomized, double-blind, crossover protocol. Three hours after drug intake, heart rate and blood pressure were measured at rest, after 10 min of exercise, and after 15 min of recovery.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Airway Receptors
    Postgraduate Medical Journal (1989) 65, 532- 542 Postgrad Med J: first published as 10.1136/pgmj.65.766.532 on 1 August 1989. Downloaded from Mechanisms of Disease Airway receptors Peter J. Barnes Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6L Y, UK. Introduction Airway smooth muscle tone is influenced by many indirect action which, in part, is due to activation of a hormones, neurotransmitters, drugs and mediators, cholinergic reflex, since the bronchoconstriction may which produce their effects by binding to specific be reduced by a cholinergic antagonist. Other surface receptors on airway smooth muscle cells. mediators may have a bronchoconstrictor effect Bronchoconstriction and bronchodilatation may which, in the case of adenosine, is due to mast cell therefore be viewed in terms of receptor activation or mediator release,2 or in the case of platelet-activating blockade and the contractile state of airway smooth factor due to platelet products.3 muscle is probably the resultant effect of interacting excitatory and inhibitory receptors. Epithelial-derived relaxantfactor It is important to recognize that airway calibre is not only the result of airway smooth muscle tone, but in Recently there has been considerable interest in the asthma it is likely that airway narrowing may also be possibility of a relaxant factor released from airway explained by oedema of the bronchial wall (resulting epithelial cells, which may be analogous to relaxant factor.4 The presence of from microvascular leakage) and to luminal plugging endothelial-derived by copyright. by viscous mucus secretions and extravasated plasma airway epithelium in bovine airways in vitro reduces proteins, which may be produced by a 'soup' of the sensitivity to and maximum contractile effect of mediators released from inflammatory cells, including spasmogens, such as histamine, acetylcholine or mast cells, macrophages and eosinophils.
    [Show full text]
  • Provider- Pain Quick Reference Guide
    A QUICK REFERENCE GUIDE (2019) PBM Academic Detailing Service Posttraumatic Stress Disorder A VA Clinician's Guide to Optimal Treatment of Posttraumatic Stress Disorder (PTSD) VA PBM Academic Detailing Service Real Provider Resources Real Patient Results Your Partner in Enhancing Veteran Health Outcomes VA PBM Academic Detailing Service Email Group [email protected] VA PBM Academic Detailing Service SharePoint Site https://vaww.portal2.va.gov/sites/ad VA PBM Academic Detailing Public Website http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp Table of Contents Abbreviations . 1 PTSD Treatment Decision Aid . 3 VA/DoD 2017 Clinical Practice Guideline: Treatment of PTSD . 4 First-Line Treatment: Trauma-focused Psychotherapies with the Strongest Evidence . 5 First-Line Treatment: Trauma-Focused Psychotherapies with Sufficient Evidence . 6 Comparison of Antidepressants Studied in PTSD . 7 Recommended Antidepressant For PTSD: Dosing . 9 Additional Medications Studied in PTSD: Dosing . 11 Switching Antidepressants . 12 Antidepressants and Sexual Dysfunction . 14 i TOC (continued) Sexual Dysfunction Treatment Strategies . 16 Antidepressants and Hyponatremia . 17 Additional Pharmacotherapy Options for Veterans Refractory to Standard Treatments . 19 Discussing Benzodiazepine Withdrawal . 21 Prazosin Tips . 25 Prazosin Precautions . 26 Managing PTSD Nightmares in Veterans with LUTS Associated with BPH . 27 Other Medications Studied in PTSD-Related Nightmares . 29 References . 30 ii Abbreviations Anti-Ach = anticholinergic
    [Show full text]